Hip Pelvis.  2019 Dec;31(4):232-237. 10.5371/hp.2019.31.4.232.

Comparison of Functional Outcomes and Associated Complications in Patients Who Underwent Total Hip Arthroplasty for Femoral Neck Fracture in Relation to Their Underlying Medical Comorbidities

• Park BY
• Lim KP
• Shon WY
• Shetty YN
• Heo KS

• KMID: 2464240
• DOI: http://doi.org/10.5371/hp.2019.31.4.232

Abstract

PURPOSE
In patients with independent mobility, full hip range of motion and sufficient muscle strength for daily life without cognitive impairment, treatment of a femoral neck fracture with total hip arthroplasty (THA) may be a better option compared to bipolar hip hemiarthroplasty. Here, functional outcomes and complications in patients who underwent THA for femoral neck fracture based on their comorbidity status were analyzed.
MATERIALS AND METHODS
Between January 2013 and December 2018, 110 patients were treated with THA for femoral neck fractures at our institution. These patients were retrospectively analyzed for clinical outcomes at final follow-up (mean=24.4 months, range: 6-81 months) using the Harris hip score (HHS) and the presence or absence of two potential comorbidities: i) diabetes mellitus (DM; 35 with and 75 without) and ii) hypertension (HTN; 50 with and 60 without).
RESULTS
The incidence of superficial infections at the surgical site in patients with DM was significantly higher compared with patients without DM (P=0.024). There were no significant differences in other potential complications based on DM status. HHS at final follow-up between patients with and without DM and with and without HTN were not significantly different (83.3 vs. 81.0, P=0.39 and 81.6 vs. 82.4, P=0.75, respectively).
CONCLUSION
Superficial infections occurred more frequently in patients with DM compared with patients without DM. DM and HTN status are not correlated with HHS.

Keyword

Femoral neck fractures; Total hip arthroplasty; Comorbidity; Superficial infection

MeSH Terms

Arthroplasty, Replacement, Hip*
Cognition Disorders
Comorbidity*
Diabetes Mellitus
Femoral Neck Fractures*
Femur Neck*
Follow-Up Studies
Hemiarthroplasty
Hip
Humans
Hypertension
Incidence
Muscle Strength
Range of Motion, Articular
Retrospective Studies

Reference

1. Bozic KJ, Ries MD. The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. J Bone Joint Surg Am. 2005; 87:1746–1751. PMID: 16085614.

2. Ridgeway S, Wilson J, Charlet A, Kafatos G, Pearson A, Coello R. Infection of the surgical site after arthroplasty of the hip. J Bone Joint Surg Br. 2005; 87:844–850. PMID: 15911671.

3. Bozic KJ, Ward DT, Lau EC, et al. Risk factors for periprosthetic joint infection following primary total hip arthroplasty: a case control study. J Arthroplasty. 2014; 29:154–156. PMID: 23702271.

4. Poultsides LA, Ma Y, Della Valle AG, Chiu YL, Sculco TP, Memtsoudis SG. In-hospital surgical site infections after primary hip and knee arthroplasty: incidence and risk factors. J Arthroplasty. 2013; 28:385–389. PMID: 23142444.

5. Dale H, Fenstad AM, Hallan G, et al. Increasing risk of prosthetic joint infection after total hip arthroplasty. Acta Orthop. 2012; 83:449–458. PMID: 23083433.

6. Everhart JS, Altneu E, Calhoun JH. Medical comorbidities are independent preoperative risk factors for surgical infection after total joint arthroplasty. Clin Orthop Relat Res. 2013; 471:3112–3119. PMID: 23519927.

7. Namba RS, Inacio MC, Paxton EW. Risk factors associated with surgical site infection in 30,491 primary total hip replacements. J Bone Joint Surg Br. 2012; 94:1330–1338. PMID: 23015556.

8. Kannus P, Parkkari J, Sievänen H, Heinonen A, Vuori I, Järvinen M. Epidemiology of hip fractures. Bone. 1996; 18:57S–63S. PMID: 8717549.

9. Avery PP, Baker RP, Walton MJ, et al. Total hip replacement and hemiarthroplasty in mobile, independent patients with a displaced intracapsular fracture of the femoral neck: a seven- to ten-year follow-up report of a prospective randomised controlled trial. J Bone Joint Surg Br. 2011; 93:1045–1048. PMID: 21768626.

10. Lai K, Bohm ER, Burnell C, Hedden DR. Presence of medical comorbidities in patients with infected primary hip or knee arthroplasties. J Arthroplasty. 2007; 22:651–656. PMID: 17689771.

11. Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res. 2008; 466:1710–1715. PMID: 18421542.

12. van Vugt AB, Oosterwijk WM, Goris RJ. Osteosynthesis versus endoprosthesis in the treatment of unstable intracapsular hip fractures in the elderly. A randomised clinical trial. Arch Orthop Trauma Surg. 1993; 113:39–45. PMID: 8117509.

13. Bozic KJ, Lau E, Kurtz S, et al. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. J Bone Joint Surg Am. 2012; 94:794–800. PMID: 22552668.

14. Song KH, Kim ES, Kim YK, et al. Differences in the risk factors for surgical site infection between total hip arthroplasty and total knee arthroplasty in the Korean Nosocomial Infections Surveillance System (KONIS). Infect Control Hosp Epidemiol. 2012; 33:1086–1093. PMID: 23041805.

15. Paxton EW, Inacio MC, Singh JA, Love R, Bini SA, Namba RS. Are there modifiable risk factors for hospital readmission after total hip arthroplasty in a US healthcare system? Clin Orthop Relat Res. 2015; 473:3446–3455. PMID: 25845947.

16. Proceedings of the international consensus meeting on periprosthetic joint infection. Foreword. J Orthop Res. 2014; 32 Suppl 1:S2–S3. PMID: 24464894.

17. Golden SH, Peart-Vigilance C, Kao WH, Brancati FL. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care. 1999; 22:1408–1414. PMID: 10480501.

18. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009; 15:353–369. PMID: 19454396.

19. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992; 13:606–608. PMID: 1334988.

20. Ousey K, Djohan R, Dowsett C, et al. Surgical wound dehiscence: improving prevention and outcomes. Wounds UK. 2018; 1:48.

21. Travis EC, Tan RS, Funaki P, McChesney SJ, Patel SC, Brogan K. Clinical outcomes of total hip arthroplasty for fractured neck of femur in patients over 75 years. J Arthroplasty. 2015; 30:230–234. PMID: 25311164.

22. Berry DJ, von Knoch M, Schleck CD, Harmsen WS. Effect of femoral head diameter and operative approach on risk of dislocation after primary total hip arthroplasty. J Bone Joint Surg Am. 2005; 87:2456–2463. PMID: 16264121.

23. van Kasteren ME, Manniën J, Ott A, Kullberg BJ, de Boer AS, Gyssens IC. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. Clin Infect Dis. 2007; 44:921–927. PMID: 17342642.

24. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999; 16:1906–1912.

25. Eibl N, Spatz M, Fischer GF, et al. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol. 2002; 103(3 Pt 1):249–259. PMID: 12173299.

26. Pozzilli P, Gale EA, Visalli N, et al. The immune response to influenza vaccination in diabetic patients. Diabetologia. 1986; 29:850–854. PMID: 3569690.

27. Marchant MH Jr, Viens NA, Cook C, Vail TP, Bolognesi MP. The impact of glycemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty. J Bone Joint Surg Am. 2009; 91:1621–1629. PMID: 19571084.

28. Maradit Kremers H, Lewallen LW, Mabry TM, Berry DJ, Berbari EF, Osmon DR. Diabetes mellitus, hyperglycemia, hemoglobin A1C and the risk of prosthetic joint infections in total hip and knee arthroplasty. J Arthroplasty. 2015; 30:439–443. PMID: 25458090.

29. Jain NB, Guller U, Pietrobon R, Bond TK, Higgins LD. Comorbidities increase complication rates in patients having arthroplasty. Clin Orthop Relat Res. 2005; (435):232–238.

30. England SP, Stern SH, Insall JN, Windsor RE. Total knee arthroplasty in diabetes mellitus. Clin Orthop Relat Res. 1990; (260):130–134.

31. Forrest G, Fuchs M, Gutierrez A, Girardy J. Factors affecting length of stay and need for rehabilitation after hip and knee arthroplasty. J Arthroplasty. 1998; 13:186–190. PMID: 9526212.

32. Serna F, Mont MA, Krackow KA, Hungerford DS. Total knee arthroplasty in diabetic patients. Comparison to a matched control group. J Arthroplasty. 1994; 9:375–379. PMID: 7964768.

33. Yang K, Yeo SJ, Lee BP, Lo NN. Total knee arthroplasty in diabetic patients: a study of 109 consecutive cases. J Arthroplasty. 2001; 16:102–106. PMID: 11172278.

34. Chun YS, Lee SH, Lee SH, Cho YJ, Rhyu KH. Clinical implication of diabetes mellitus in primary total hip arthroplasty. Hip Pelvis. 2014; 26:136–142. PMID: 27536571.

35. Perka C, Arnold U, Buttgereit F. Influencing factors on perioperative morbidity in knee arthroplasty. Clin Orthop Relat Res. 2000; (378):183–191.

36. Freedman DS, Khan LK, Serdula MK, Galuska DA, Dietz WH. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA. 2002; 288:1758–1761. PMID: 12365960.